Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Abroad (travel likely)RecruitingPHASE3

Conditions

Systemic Sclerosis · Interstitial Lung Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Centrum Wsparcia Badań Klinicznych, Warsaw, Masovian Voivodeship, Poland
Contact: Study coordinator (Justyna Kwiatkowska-Golańska) · justyna.kwiatkowska-golanska@spartanska.pl · 22 6880632
Contact: Principal Investigator (Maria Maślińska, PhD, MD)

Study leads

Maria Maślińska, PhD, MD
Principal Investigator
National Institute of Geriatrics,Rheumatology and Rehabilitation

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

Systemic Sclerosis With Lung Involvement · Systemic Sclerosis · Interstitial Lung Disease

Abroad (travel likely)RecruitingPHASE2

Montreal, Canada · Montreal, Canada

Connective Tissue Diseases and Lung Manifestations

Connective Tissue Diseases · Interstitial Lung Disease · Systemic Sclerosis

Abroad (travel likely)Recruiting

Innsbruck, Austria

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Systemic Sclerosis

Abroad (travel likely)RecruitingPHASE3

Scottsdale, United States · Aurora, United States

Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

Systemic Sclerosis (SSc) · Hand Dysfunction

Abroad (travel likely)Recruiting

Guangzhou, China · Shanghai, China